Company: PTPI
Filing Date: 2025-01-24
Form Type: S-1
Source: 0001410578-25-000047
Chunk: 76

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-01-24
Form: S-1
Chunk 76
---
 as of September 30, 2024)                                                                                                                             | ​ | ​                        |        1,002 | ​ | ​                     |        1,002 | ​ |                            | ​ |
| Additional paid-in capital                                                                                                                                                                                                                                                                     | ​ | ​                        |  107,049,640 | ​ | ​                     |  107,049,640 | ​ |                            | ​ |
| Accumulated deficit                                                                                                                                                                                                                                                                            | ​ | ​                        | -103,934,931 | ​ | ​                     | -109,072,063 | ​ |                            | ​ |
| Total Stockholders’ Equity                                                                                                                                                                                                                                                                     | ​ | $                        |    3,115,711 | ​ | $                     |   -2,021,421 | ​ |                            | ​ |
| Total Capitalization                                                                                                                                                                                                                                                                           | ​ | $                        |   20,693,630 | ​ | $                     |   13,556,498 | ​ | ​                          | ​ |

43

Each $1.00 increase (decrease) in the assumed public offering price per share would increase (decrease) the amount of cash and cash equivalents, working capital, total assets, and total stockholders’ equity by $ , assuming the number of securities offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the placement agent fees and estimated offering expenses payable by us. We may also increase or decrease the number of securities to be issued in this offering. Each increase (decrease) of 1.0 million Units offered by us would increase (decrease) the as adjusted amount of cash and cash equivalents, working capital, total assets and total stockholders’ equity by approximately $ , assuming the assumed public offering price remains the same, and after deducting the Placement Agent fee and estimated offering expenses payable by us. The discussion and table above are based on 10,014,872 shares of our common stock outstanding as of September 30, 2024, and excludes the following:

| ● | 8,188,742 shares of common stock issuable upon exercise of the Company’s outstanding warrants at an average weighted exercise of $14.49 per share; |

| ● | 509,133 shares of common stock underlying outstanding options of the Company, with a weighted average exercise price of $4.75 per share; |

| ● | 560,171 shares of common stock issuable upon conversion of the 1,039 shares of the